-
BRL-42715
- names:
BRL-42715
- CAS號:
102209-75-6
MDL Number: - MF(分子式): C10H7N4NaO3S MW(分子量): 286.24
- EINECS: Reaxys Number:
- Pubchem ID:23705463 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (¥) | 現(xiàn)價(¥) | 特價(¥) | 庫存描述 | 數(shù)量 | 總計 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000400-100mg | 100mg | >97% | ¥ 0.00 | ¥ 0.00 | 2-3天 | ¥ 0.00 |
- 大包裝詢價 提供各種包裝,敬請垂詢
- 收藏商品 商品點(diǎn)評 加入購物車 立即購買
| 中文別名 | BRL-42715(102209-75-6),Brl-42715,Brl42715,Brl 42715 |
| 英文別名 | BRL-42715(102209-75-6),Brl-42715,Brl42715,Brl 42715 |
| CAS號 | 102209-75-6 |
| Inchi | InChI=1S/C10H8N4O3S.Na/c1-13-3-5(11-12-13)2-6-8(15)14-7(10(16)17)4-18-9(6)14;/h2-4,9H,1H3,(H,16,17);/q;+1/p-1/b6-2+;/t9-;/m1./s1 |
| InchiKey | OMJBLZMKGVWHQP-MPXWGJQKSA-M |
| 分子式 Formula | C10H7N4NaO3S |
| 分子量 Molecular Weight | 286.24 |
| 溶解度Solubility | |
| 性狀 | Solid |
| 儲藏條件 Storage conditions | 請根據(jù)產(chǎn)品建議的存儲條件進(jìn)行存儲,Please store the product under the recommended condition sin the description. |
1.實驗前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲,并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:BRL-42715蒸汽壓,BRL-42715合成,BRL-42715標(biāo)準(zhǔn),BRL-42715應(yīng)用,BRL-42715合成,BRL-42715沸點(diǎn),BRL-42715閃點(diǎn),BRL-42715用途,BRL-42715溶解度,BRL-42715價格,BRL-42715作用,BRL-42715結(jié)構(gòu)式,BRL-42715用處
| 產(chǎn)品說明 | BRL-42715 (102209-75-6)是一種有效的廣泛的細(xì)菌β-內(nèi)酰胺酶的有效的抑制劑 |
| Introduction | BRL-42715 (102209-75-6) is a potent inhibitor of a broad range of bacterialbetaactamases (βactamase). |
| Application1 | |
| Application2 | |
| Application3 |
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實驗過程中防止吸入、食入,做好安全防護(hù) |
| Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin PMID 1669013; The Journal of antimicrobial |
| In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam PMID 8262864; The Journal of antimicrobial chemotherapy 1993 Sep; 32(3):421-9 Name match |
| SYN-1012: a new beta-lactamase inhibitor of penem skeleton PMID 9186563; The Journal of antibiotics 1997 Apr; 50(4):350-6 Name matches: clavulanate; clavulanic acid brl-42715 |
| Evolution of beta-lactamase inhibitors PMID 2041830; Pharmacotherapy 1991; 11(2 ( Pt 2)):37S-39S Name matches: sulbactam brl-42715 |
| Outer membrane permeability of beta-lactamase inhibitors in Pseudomonas aeruginosa PMID 7607408; FEMS microbiology letters 1995 Jun; 129(2-3):251-4 Name matches: beta-lactamase brl42715 |
Abstract:The β-lactamases of seven strains ofAeromonas salmonicida subsp.achromogenes resistant to amoxicillin (MIC>1024 mg/l) and responsible for furunculosis in farmed Atlantic salmon in Scotland were examined to establish the mechanisms of β-lactam resistance. Separation of a cell-free extract on an isoelectric focusing gel stained with the chromogenic cephalosporin nitrocefin showed the presence of two β-lactamases, one with a pI of 7.9 and the other with a pI of 6.0. Hydrolysis assays of cell-free extracts of these strains demonstrated carbapenemase, penicillinase and cephalosporinase activity. However, when the β-lactamases were separated by anion exchange chromatography, the carbapenemase activity could not be retrieved in either of the peak fractions containing the separated enzymes that had been visualised by nitrocefin. Consequently, a novel carbapenemase was discovered which cannot be detected with nitrocefin.
2.Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents inPseudomonas aeruginosa European Journal of Clinical Microbiology and Infectious Diseases 1995
Abstract:Eighty-nine clinical isolates resistant (n=61) or susceptible (n=28) to imipenem and exhibiting the main patterns of susceptibility to other β-lactam agents (wild type pattern, penicillinase pattern, constitutive cephalosporinase pattern) were studied in order to investigate (i) the mechanism of resistance involved and (ii) whether resistance to carbapenems affects the level of resistance to other β-lactam agents and, conversely, if resistance to other β-lactam agents affects the level of resistance to carbapenems. For this purpose, the presence of OprD protein in the cell wall was detected by Western blot and β-lactamase activity by spectrophotometric assay and isoelectric focusing. OprD expression was not detectable in the imipenem-resistant (MIC≥16 μg/ml) strains. It was decreased in half the strains for which MICs of imipenem were 2 to 8 μg/ml and was close to a normal level in the most susceptible strains (MIC ≤1 μg/ml), thus demonstrating a direct correlation between the level of susceptibility to imipenem and the level of OprD expression. No imipenemase activity was detected in imipenem-resistant strains. Synergy between imipenem or meropenem and BRL42715 was observed for all of the strains, demonstrating the role of cephalosporinase in carbapenem resistance. Within each pattern of susceptibility, the mean MICs of β-lactam agents other than carbapenems were similar, whether the strains were susceptible or resistant to imipenem. Conversely, the mean MICs of imipenem or meropenem for either the imipenem-resistant or the imipenem-susceptible strains were similar, regardless of the susceptibility of these strains to the other β-lactam agents. Thus, when several mechanisms of resistance to β-lactam agents are present in the same strain ofPseudomonas aeruginosa, there is no additive effect between these mechanisms.
3.Synthesis of 6-exomethylenepenams as β-lactamase inhibitors Archives of Pharmacal Research 1999
Abstract:The 6,6-dibromopenam (6) was treated with CH3MgBr and carbaldehyde5 to afford the hydroxy compound7, which was reacted with acetic anhydride to give acetoxy compound8. The deacetobromination of8 with zinc and acetic acid gave 6-exomethylenepenams,E-isomer10 andZ-isomer9, which was oxidized to sulfone11 bym-CPBA. Thep-methoxybenzyl compounds were deprotected by AlCl3 and neutralized to give the sodium salts12, 13 and14.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實驗
細(xì)胞爬片免疫組化染色,是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長,主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實驗方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實驗室封口膜:技術(shù)與國際市場的雙重突破
在實驗室耗材領(lǐng)域,封口膜是保障實驗準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來,Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個重要因素是:微流控...
2023/7/27 12:44:28

熒光素鉀鹽使用說明
D-熒光素鉀鹽(K+)設(shè)計用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問題
牛血清白蛋白(BSA)常見問題:牛血清白蛋白(BSA)在實驗室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購物車 


